Objective-Smooth muscle (SM) 22α, an actin-binding protein, displays an upregulated expression as a marker during cellular senescence. However, the causal relationship between SM22α and senescence is poorly understood. This study aimed to investigate the role of SM22α in angiotensin II (Ang II)-induced senescence of vascular smooth muscle cells (VSMCs). Approach and Results-We prepared a model of VSMC senescence induced by Ang II and found that the expression of SM22α in VSMCs was increased in response to chronic Ang II treatment. Overexpression of SM22α promoted Ang IIinduced VSMC senescence, whereas knockdown of SM22α suppressed this process. Moreover, this effect of SM22α was p53 dependent. Increased SM22α protein obstructed ubiquitination and degradation of p53 and subsequently improved its stability. Furthermore, SM22α inhibited phosphorylation of Mdm2 (mouse double minute 2 homolog), an E3 ubiquitin-protein ligase, accompanied by a decreased interaction between Mdm2 and p53. Using LY294002, a PI3K/Akt inhibitor, we found that PI3K/Akt-mediated Mdm2 phosphorylation and activation was inhibited in senescent or SM22α-overexpressed VSMCs, in parallel with decreased p53 ubiquitination. We further found that SM22α inhibited activation of PI3K/Akt/Mdm2 pathway via strengthening actin cytoskeleton. In the in vivo study, we showed that the disruption of SM22α reduced the increase of blood pressure induced by Ang II, associated with decreased VSMC senescence through a mechanism similar to that in VSMCs in vitro. Conclusions-In conclusion, these findings suggest that the accumulation of SM22α promotes Ang II-induced senescence via the suppression of Mdm2-mediated ubiquitination and degradation of p53 in VSMCs in vitro and in vivo. Visual Overview-An online visual overview is available for this article. inhibits VSMC proliferation and neointimal formation induced by balloon injury via blockade of the Ras/ERK1/2 signaling pathway. 19 The studies in mammalian cells have shown that the expression of SM22α is increased in senescent cells. [19] [20] [21] The upregulation of SM22α expression is associated with the normal human fibroblast transforming to a state close to replicative senescence under sublethal oxidative stress.
S
enescence of vascular smooth muscle cells (VSMCs) contributes to the pathogenesis of vascular disease. [1] [2] [3] [4] Cellular senescence is a permanent and irreversible cell growth arrest state, which is usually characterized by enlarged and flattened shape, accompanied by alteration of cell function and gene expression, such as elevated p53 and p21, negative regulators of the cell cycle, and the increase of senescence-associated β-galactosidase (SA-β-gal) activity, a biomarker of cellular senescence. 5, 6 These changes have been implicated in aging and age-related vascular disorder. 7 Although the function of cellular senescence has been extensively examined, its underlying molecular mechanism remains elusive.
Angiotensin II (Ang II) plays a pluripotent role in the pathogenesis of cardiovascular disease, including atherosclerosis and hypertension. 8, 9 Numerous studies suggest that Ang II is a potent mediator of oxidative stress 10 contributing to vascular damage through activation of multiple signaling pathways. Although Ang II has always been considered as a critical regulator of VSMC proliferation and contraction, emerging evidence strongly supports that Ang II induces senescence of vascular cells, 11 leading to vascular remodeling and atherosclerosis. 12 It has been known that pulmonary artery smooth muscle cell senescence is an important contributor to the process of pulmonary vascular remodeling that underlies pulmonary hypertension, 13, 14 indicating that VSMC senescence may be a critical mechanism underlying hypertension.
Smooth muscle (SM) 22α is a 22 kDa cytoskeleton-associated protein and is abundantly expressed in smooth muscle cells of vertebrates. 15 Although the function of SM22α is to bind actin and regulate the organization of actin cytoskeleton, 16 recent studies show that SM22α is involved in various cell behaviors via affecting different signaling pathway and plays a key role in pathogenesis of atherosclerosis and tumors. 17, 18 We found that the overexpression of SM22α October 2017
inhibits VSMC proliferation and neointimal formation induced by balloon injury via blockade of the Ras/ERK1/2 signaling pathway. 19 The studies in mammalian cells have shown that the expression of SM22α is increased in senescent cells. [19] [20] [21] The upregulation of SM22α expression is associated with the normal human fibroblast transforming to a state close to replicative senescence under sublethal oxidative stress. 22 SM22a overexpression promotes HepG2 cell senescence caused by a subclinical dose of c-radiation and doxorubicin, 23 indicating that SM22α is involved in cellular senescence. SM22α-mediated actin stabilization may trigger cell death and dysfunction. 24 We also found that there was an increased SM22α expression in the aortic tissues of spontaneously hypertensive rats and Ang II-induced hypertension rats (Mei Han, unpublished data, 2015) . Furthermore, the overexpression of SM22α upregulates the level of cyclin-dependent kinase inhibitors p21 and p27 proteins. 25 However, the causal relationship between the increased SM22α and senescence is poorly understood.
Tumor suppressor protein p53 plays a central role in cellular senescence through the activation of cyclin-dependent kinase inhibitor p21. 26, 27 Activation of p53/p21 pathway by oxidative stress or DNA damage contributes to VSMC senescence induced by Ang II. 12, 28 Recent study shows that the transfection of SM22α results in the upregulation of p53 expression and induces apoptosis of human prostate LNCaP cells through its interaction with p53. 29 However, the significances of interaction between SM22α and p53 during VSMC senescence remain to be elucidated.
In the present study, we demonstrated that the level of SM22α expression gradually increased during Ang II-induced VSMC senescence. This increased SM22α protein facilitated VSMC senescence through inhibition of Mdm2 (mouse double minute 2 homolog)-mediated p53 ubiquitination and degradation in vitro. High expression of SM22α inhibited phosphorylation and activation of Mdm2 by Akt via strengthening actin cytoskeleton. We also found that SM22α was implicated in Ang II-induced senescence of VSMCs in vivo with the same mechanism as in vitro. Our findings suggest that SM22α plays a positive role in VSMC senescence induced by Ang II and may provide a novel target for aging-associated cardiovascular disease treatment.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
Results

The Expression of SM22α Is Increased in Ang II-Induced VSMC Premature Senescence and in Aortas of Aged Mice
The previous studies have demonstrated that Ang II induces VSMC senescence in vitro. 12, 28 We first reproduced this model and showed that Ang II induced VSMC senescence in a time-and dose-dependent manner ( Figure I in the onlineonly Data Supplement). Rat VSMCs were treated with Ang II (100 nmol/L) for 5 days and then were collected to examine whether cellular senescence occurred. After chronic treatment with Ang II, VSMCs displayed an enlarged size and flattened morphology, which are characteristic phenotype of senescent VSMCs. Then we used SA-β-gal staining, a classical method for determining cellular senescence, to detect senescent VSMCs. We showed that SA-β-gal-positive cells were significantly increased after chronic Ang II stimulation ( Figure 1A ). To further confirm this finding, we examined the expression level of p53, p21, and p16 which are used as markers in senescent cells. As expected, Ang II increased the expression of p53, p21, and p16 ( Figure 1B) . However, the level of PCNA (proliferating cell nuclear antigen, a marker of cell growth) protein decreased under the same conditions, which displayed an inverse change with the expression profile of the senescence markers ( Figure 1B ). Because DNA damage has been implicated in Ang II-induced VSMC senescence, we next examined the expression of γ-H2AX, a marker of DNA damage. The result showed that γ-H2AX expression increased after treatment with Ang II (Figure 1B) , further supporting the notion that chronic stimulation of Ang II induces VSMC senescence.
To determine the association of SM22α with Ang IIinduced VSMC senescence, we simultaneously detected the expression of SM22α. We showed that protein expression of SM22α was increased in parallel with VSMC senescence ( Figure 1C ) and was consistent with the mRNA expression ( Figure 1D ), whereas the ubiquitination of SM22α was not changed ( Figure 1E ). In addition, our in vivo experiments revealed that the expression of SM22α was increased in aortas of aged mice compared with control group, accompanied with increase of p53, p21, and p16 levels ( Figure 1F ). Taken together, the results showed that expression of SM22α is increased in Ang II-induced VSMC premature senescence and in aortas of aged mice, speculating that SM22α may be involved in VSMC senescence.
SM22α Promotes Ang II-Induced Premature Senescence via p53 in VSMCs
To validate our speculation, VSMCs were transfected with specific SM22α small interfering RNA (siSM22α) system to silence SM22α expression or infected with Ad-GFP-SM22α to overexpress it, respectively. Knockdown of SM22α significantly decreased the number of SA-β-gal-positive cells in Ang II-treated VSMCs (Figure 2A 
SM22α Inhibits Ubiquitination of p53
To explore how SM22α increases expression of p53, we examined the effects of SM22α on transcription and posttranslational modification of p53, respectively. We found that both knockdown and overexpression of SM22α had no effect on the mRNA level of p53 compared with control group ( Figure 3A and 3B). Previous studies have shown that p53 activity is mainly regulated by ubiquitination, which facilitates degradation of p53 via ubiquitin-proteasome system. 30 We next tested the effect of SM22α on p53 ubiquitination. We showed that knockdown of SM22α significantly increased p53 ubiquitination compared with control group ( Figure 3C ), and overexpression of SM22α reduced it in chronic Ang II-treated VSMCs ( Figure 3D ). However, SM22α did not change the level of p53 ubiquitination in untreated VSMCs. Collectively, the data demonstrate that SM22α enhances p53 stability via inhibition of its ubiquitination and degradation during Ang II-induced senescence of VSMCs.
SM22α Inhibits Interaction of Mdm2 With p53 in Senescent VSMCs
Mdm2, known as E3 ubiquitin-protein ligase, can promote p53 protein ubiquitination and degradation by the proteasome pathway. 31, 32 To explore the mechanism underlying SM22α inhibiting p53 ubiquitination, we examined the effect of SM22α on the interaction between Mdm2 and p53 in VSMCs. The whole cellular lysate from VSMCs treated with Ang II was immunoprecipitated with an anti-p53 antibody, and the immunoprecipitates were examined with an antibody against Mdm2. The results showed that knockdown of SM22α led to an enhanced interaction of Mdm2 with p53, which was abolished by overexpression of SM22α ( Figure 4A ). Immunofluorescent staining also showed that p53 colocalized with Mdm2 in VSMCs, which increased in VSMCs transfected with siSM22α and decreased in VSMCs infected with Ad-GFP-SM22α ( Figure 4B ).To further verify that SM22α inhibits Mdm2-mediated p53 ubiquitination during Ang II-induced senescence, we used nutlin-3, an inhibitor of p53 and Mdm2 proteins interaction, to treat VSMCs. We found that nutlin-3 pre-treatment markedly decreased the interaction between p53 and Mdm2 in chronic Ang IIinduced VSMCs with knockdown of SM22α ( Figure 4C) , accompanied by increased level of p53 and p21 under the same conditions ( Figure 4D) . Similarly, SA-β-gal staining also displayed that nutlin-3 pre-treatment resulted in increased senescent VSMCs, which eliminated the inhibitory effect of knockdown of SM22α on cellular senescence ( Figure 4E ), indicating that Mdm2 may be a target for SM22α inducing senescence.
SM22α Inhibits the Activation of Akt/Mdm2 Pathway via Strengthening Actin Cytoskeleton
Previous studies have shown that Akt/Mdm2 pathway is involved in the ubiquitination and degradation of p53. 33 Mdm2 phosphorylation is crucial for its activity regulation. Akt activates Mdm2 by phosphorylation at ser166 and consequently facilitates it interaction with p53. 34 To determine whether SM22α inhibits Mdm2 activation through Akt/Mdm2 pathway, we examined Mdm2 phosphorylation after knockdown or overexpression of SM22α. We showed that knockdown of SM22α increased phosphorylation levels of Akt and Mdm2 in chronic Ang II-induced VSMCs ( Figure 5A ). Conversely, overexpression of SM22α decreased it. To further confirm that Akt mediates Mdm2 phosphorylation, we used a PI3K/ Akt inhibitor, LY294002, to pretreat VSMCs. We found that the inhibition of Akt activity resulted in a decrease in phosphorylated Mdm2 level and an increase in p53 and p21 expression ( Figure 5B) . Meanwhile, chronic Ang II stimulation-induced senescence could not be abolished by knockdown of SM22α after inhibition of Akt ( Figure 5C ), which displayed increased senescent cells. Taken together, the data indicate that SM22α may interfere with Akt/Mdm2 pathway and then prevent p53 from ubiquitination and degradation.
As a cytoskeleton-associated protein, the basic molecular function of SM22α is to bind actin and facilitate actin filament assembly. 16 The actin cytoskeleton not only controls cell shape and motility but also plays an important role in many signaling pathways. 35, 36 Next, we investigated the mechanism underlying SM22α blocking Akt/Mdm2 pathway. We hypothesized that SM22α stabilizing the actin cytoskeleton contributes to Ang II-induced senescence. We examined the actin cytoskeleton organization in senescent VSMCs. Phalloidin staining showed that senescent VSMCs that were generated by Ang II treatment and SA-β-gal positive, displayed a dense F-actin network ( Figure 5D, left) . Similar changes were observed in VSMCs treated with jasplakinolide, an actin-stabilizing agent, even if knockdown of SM22α which resulted in decreased SA-β-gal activity accompanied with thin and scattered F-actin cytoskeleton in VSMCs ( Figure 5D , middle and right). We then examined whether the dynamic quality of F-actin cytoskeleton is implicated in Akt/Mdm2 pathway in VSMC senescence. Jasplakinolide pre-treatment abolished increased Akt and Mdm2 phosphorylation by knockdown of SM22α ( Figure 5E ), in parallel with the decreased interaction of Akt with Mdm2 ( Figure III in the online-only Data Supplement). Moreover, the senescence markers p53, p21, and SA-β-gal activity were enhanced under the same conditions ( Figure 5E and 5F). These data suggested that the dense filamentous mesh in VSMCs with high expression of SM22α may affect the interaction of these signaling proteins, resulting in enhanced p53 activity.
Depletion of SM22α Inhibits Ang IIInduced Senescence In Vivo and Improves Hypertension Induced by Ang II in Mice
To investigate whether SM22α has the same effect on VSMC senescence in vivo, we treated Ldlr −/− /Sm22α +/+ and Ldlr −/− / Sm22α −/− mice with Ang II (1.44 mg/kg per day) infusion for 4 weeks. We showed that SA-β-gal-positive cells in the aortic media of Sm22α −/− mice were less than that in wildtype (WT) mice ( Figure 6A) . Similarly, the expression of p53 and p21 decreased in the aortic tissues of Sm22α −/− mice compared with in WT mice ( Figure 6B ), accompanied with increased phosphorylation of Akt and Mdm2 ( Figure 6C ). Meanwhile, we measured systolic blood pressure (SBP) and diastolic blood pressure (DBP) of SM22α WT and Sm22α −/− mice to test the relationship between the expression of SM22α and hypertension. The data showed that both SBP and DBP were markedly lower in Sm22α −/− mice than that in the WT group ( Figure 6D ). In addition, the expression of SM22α, p53, p21, and p16 was increased in artery samples from patients with hypertension, compared with control groups (Figure 6E ), suggesting that high expression of SM22α may be associated with the elevation of blood pressure. Taken together, these results indicate that the accumulation of SM22α contributes to vascular aging in vivo via inhibiting Akt/Mdm2-mediated p53 degradation.
Discussion
In the present study, we found that the level of SM22α was significantly increased in Ang II-induced VSMC senescence, and the overexpression of SM22α aggravated VSMC senescence. This role of SM22α was associated with the upregulation of p53 expression in vitro. Moreover, increased SM22α suppressed the activation of Akt/Mdm2 pathway and subsequently decreased the activity and interaction of Mdm2 with p53 by inhibition of actin cytoskeletal dynamics, thereby SM22α, as a shape change and transformation-sensitive protein, is involved in regulation of cytoskeletal rearrangement and maintenance of differentiated phenotype of VSMCs. 16 Our previous studies have demonstrated that the disruption of SM22α damages vascular functions via promoting VSMC phenotype switching. 37 However, elevated SM22α expression also serves as a marker of cellular senescence. 20, 21 Studies have found that SM22α is overexpressed in senescent human diploid fibroblasts and human diploid fibroblasts from a patient with Werner syndrome a premature aging disorder. 38 Deletion of Scp1p, an actin-bundling protein in yeast which has homology with mammalian SM22α, leads to significant increase in longevity, 39 indicating that SM22α may be involved in cell senescence. Here, we showed that the level of SM22α was significantly increased in Ang II-induced VSMC senescence. Knockdown or overexpression of SM22α attenuated or accelerated VSMC senescence induced by Ang II, respectively. Our findings suggest that the accumulation of SM22α in senescent VSMCs is not only a sign of senescence, but also has a certain degree of regulatory function, which may be regarded as an alternative mechanism underlying the inhibition of VSMC proliferation by SM22α. The physiological concentration of SM22α protein is critical to maintain vascular homeostasis.
P53 is a core factor in the network of senescence regulation and can be activated by various stimulation or stresses evoking cellular senescence to regulate development of senescence through activation of p21. 26 We showed that both p53 and p21 increased along with the increase of SM22α expression in the senescent VSMCs treated with Ang II and that SM22α-mediated senescence may be p53 dependent. Mdm2, an E3 ubiquitin ligase, plays a crucial role in regulation of p53 expression and activity through ubiquitination. 31 Wu et al 40 have shown that lncRNA-p21 represses cell proliferation and induces apoptosis in VSMCs by releasing Mdm2 repression of p53 and enhance p53 transcriptional activity. In the present study, we found that SM22α facilitated accumulation of p53 by inhibiting activation of Mdm2, underscoring that Mdm2-mediated p53 ubiquitination plays a key role in phenotypic modulation of VSMCs. However, Mdm2 itself is tightly regulated by the upstream molecules to maintain p53 at an appropriate level. 30 The regulation of Mdm2 activity is mainly posttranslational modification, including self-ubiquitination and particularly phosphorylation that is important for p53 activation. 33 Akt activates Mdm2 through phosphorylating Mdm2 at Ser166 and Ser186, which is upstream of the ubiquitination and degradation of p53. 31 Recent studies showed that SM22α inhibits cell proliferation by suppressing activity of Akt. 41, 42 We found that upregulation of SM22α suppressed phosphorylation of Akt and Mdm2 in Ang II-induced VSMC senescence, in parallel with increased p53 level, suggesting that Akt/Mdm2 pathway is responsible for the effect of promoting senescence by SM22α. Thus, our study reveals a novel regulation mechanism for Akt involved in cellular senescence. A recent report found disruption of the microtubule cytoskeleton in response to nocodazole treatment significantly reduced phosphorylation of Akt, 43 indicating that cytoskeleton is implicated in the activation of Akt. We demonstrated that stable cytoskeleton with increased SM22α facilitated VSMC senescence and blunted the activation of the Akt/Mdm2 pathway via retarding the interaction of these signaling proteins. Our data support the view that actin cytoskeleton plays a key role in the development of VSMC senescence. In the present study, we also found that Ang II induced the upregulation of ROS (reactive oxygen species), γ-H2AX, and enhanced p53 and p21 expression. Scavenging of ROS using NAC (N-acetyl-L-cysteine) resulted in reduced levels of p53 and p21 (data not shown). We thought that SM22α and ROS were involved in Ang II-induced senescence by 2 distinct mechanisms. SM22α enhanced p53 stability via inhibiting Mdm2 activation by strengthening actin cytoskeleton. However, ROS directly induced DNA damage and subsequently activated p53, and SM22α does not seem to be involved in the response. Thus, SM22α and ROS may have a synergistic effect on Ang II-induced senescence. Further study is needed to explore the relationship between SM22α and ROS in Ang II-induced VSMC senescence. A similar finding has been reported for the role of ROS in Ang II-induced senescence. 44 In the present study, Ldlr −/− /Sm22α −/− mice were generated to evaluate whether SM22α affects VSMC senescence in vivo. We found VSMC senescence was markedly retarded in SM22α knockout mice with Ang II infusion, compared with that in WT mice. Meantime, phosphorylation of Akt and Mdm2 was significantly increased, accompanied by decreased p53 and p21 proteins in the aortic wall of Sm22α −/− mice under the same conditions, in consistent with the in vitro findings, indicating that SM22α facilitates Ang II-induced vascular aging in vivo and in vitro. Increasing evidence suggests that vascular cell senescence is closely associated with the development of hypertension. 45, 46 The recent report showed that pulmonary artery smooth muscle cell senescence is a pathogenic mechanism for pulmonary hypertension. 13, 14 In the present study, we found that both SBP and DBP were significantly lower in Sm22α −/− mice than that in the SM22α WT controls. However, although we found that SM22α was increased in the artery samples from patients with hypertension, the causal relationship between Ang II and hypertension in these patients could not be determined in the present study. Taken together, our findings indicate that inhibition of VSMC senescence by knockdown of SM22α may retard the development of hypertension to some extent. 
Sources of Funding
Disclosures
None.
